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lular uptake and whole-transcriptome microarray gene expression analysis of HeLa cells
treated with a ruthenium(II)-arene complex with an isoquinoline-3-carboxylic acid lig-
and, Journal of Inorganic Biochemistry (2016), doi: 10.1016/j.jinorgbio.2016.04.011
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that















Cell cycle, apoptosis, cellular uptake and whole-transcriptome microarray gene 
expression analysis of HeLa cells treated with a ruthenium(II)-arene complex with 





















Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia 
b
 Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11 000 Belgrade, Serbia 
c
 Institute of Chemistry, Technology and Metallurgy, Centre of Chemistry, University of Belgrade, 
Studentski trg 12-16, Belgrade, Serbia 
d
 Present address: UCL Cancer Institute, University College London, London, United Kingdom 
#
 K.K. Jovanović and M. Tanić contributed equally to this work 
 
Abstract 
Ruthenium(II)-arene complexes are promising drug candidates for the therapy of solid tumors. In 





synthesized and characterized, of which the complex with L = isoquinoline-3-carboxylic acid (RuT7) 
was two times as active on HeLa cells compared to normal cell line MRC-5, as indicated by IC50 values 
determined after 48 h of incubation (45.4 ± 3.0 vs. 84.2 ± 5.7 µM, respectively). In the present study, 
cell cycle analysis of HeLa cells treated with RuT7 showed S phase arrest and an increase in sub-G1 
population. The apoptotic potential of the title compound was confirmed with the Annexin V-FITC/PI 
assay together with a morphological evaluation of cells using fluorescent microscopy. Analysis of the 
intracellular accumulation of ruthenium showed 8.9 ng Ru/10
6
 cells after 6 h of incubation. To gain 
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further insight in the molecular mechanism of action of RuT7 on HeLa cells, a whole-transcriptome 
microarray gene expression analysis was performed. Analysis of functional categories and signaling and 
biochemical pathways associated with the response of HeLa cells to treatment with RuT7 showed that it 
leads the cells through the intrinsic (mitochondrial) apoptotic pathway, via indirect DNA damage due to 
the action of reactive oxygen species, and through direct DNA binding of RuT7. Statistical analysis for 
enrichment of gene sets associated with known drug-induced toxicities identified fewer associated 
toxicity profiles in RuT7-treated cells compared to cisplatin treatment. Altogether these results provide 
the basis for further development of RuT7 in animal and pre-clinical studies as a potential drug 
candidate. 
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1. Introduction 
Since the first success of cisplatin in cancer therapy numerous alternatives to this most widely 
used chemotherapeutic agent have been proposed. Although cisplatin and its analogues (carboplatin, 
oxaliplatin) have undoubtedly been proven to be highly effective against several types of epithelial 
cancer, including ovarian, bladder and testicular cancer, these drugs display only limited therapeutic 
activity against the most common tumors, such as colon and breast cancer [1]. Taking into account the 
limited scope of cisplatin treatment, coupled with the emergence of secondary tumor resistance and a 
range of dose-limiting adverse effects, such as nephrotoxicity, peripheral neurotoxicity and 
emetogenesis, there is an imminent need for the development and clinical introduction of alternative 
antineoplastic agents [2]. 
To overcome these issues, a large number of ruthenium-based compounds have been developed 
and tested in pre-clinical studies showing high anticancer activity and fewer associated toxicities 
compared to platinum-based drugs. Three ruthenium(III) compounds have shown high in vitro and in 
vivo antitumor activity and have managed to reach clinical trials: NAMI-A (trans-[tetrachlorido(1H-















indazole) ruthenate(III)]) and NKP1339 (sodium trans-[tetrachloridobis(1H-indazole) ruthenate(III)]) 
[3-6]. NAMI-A exhibited selective activity on metastases of solid tumors, with no effect on primary 
tumor growth, while KP1019 showed pronounced cytotoxic effect, especially in colorectal tumor cells 
and carcinomas [7-9]. 
Emerging in vivo data on two prototypical compounds, [Ru(η
6
-p-cymene)(en)Cl], where en = 
ethylenediamine (RAED-C) and [Ru(η
6
-p-cymene)(pta)Cl2], where pta = 1,3,5-triaza-7-
phosphaadamantane (RAPTA-C), put the focus on ruthenium(II)-arene compounds. It was shown that 
regardless of the low in vitro activity, RAPTA-C is very active in vivo, where it inhibits lung metastases 
in CBA mice [10]. Besides supposed low general toxicity and high selectivity of ruthenium compounds 
for cancer cells, ruthenium(II)-arene complexes are characterized by hydrophobic arene ligands which 
are counterbalanced by the hydrophilic metal centre. These features, together with synthetic diversity of 
the arene ligand, make ruthenium(II)-arene compounds appealing candidates for anticancer drug design 
[11]. 







 are fluoro, chloro, bromo or 
methyl derivatives of picolinic acid or isoquinoline-3-carboxylic acid [12]. DNA binding study have 





acid (RuT7). The observed increase in absorbance (hyperchromism) of calf thymus (CT) DNA reflects 
an altered conformation of DNA double-helix via intercalation of investigated complex into DNA 
double-helix in vitro [13]. After preliminary screening of antiproliferative activity against tumor and 




















Although many of the mechanisms of action of the ruthenium-based complexes are not yet fully 
understood, besides the inhibition of the metastases [14, 15], other mechanisms have been proposed as 
well, such as interactions with DNA [16] and proteins [17], production of reactive oxygen species [18], 
inhibition of topoisomerase activity [19, 20], induction of apoptosis [21] and antiangiogenic effects [22, 
23]. Recently, studies oriented towards elucidating the molecular background of the underlying 
biological mechanisms of action of ruthenium-based complexes began to emerge. In a recent study, 
Bergamo et al. performed whole-transcriptome analysis and RNA-sequencing of the metastatic MDA-
MB-231 mammary carcinoma and non-tumorigenic HBL-100 mammary gland cells treated with 
antimetastatic agent NAMI-A, demonstrating a differential response between MDA-MB-231 and HBL-
100 cells to NAMI-A treatment, at the level of cell cycle regulation and ECM (extracellular matrix) 
remodeling in MDA-MB-231 cells [24]. In another work, a genome profiling of the human ovarian and 
cisplatin-resistant human ovarian cancer cell lines (A2780 and A2780cisR) treated with hydrazinyl-
thiazolo arene ruthenium complexes has been performed. The results have shown that these compounds 
lead both cancer cell lines through apoptotic and cell death-related processes via p53 signaling pathway, 
despite the fact that signal transduction occurs through different molecules in these cell lines [25]. 
Although still very sparse, studies regarding molecular mechanisms of ruthenium compounds action are 















In this study we have performed a comprehensive analysis of both cellular and molecular response 
to RuT7 treatment on HeLa cells. To elucidate the mode of action of RuT7 complex, gene expression 
profiling using Whole Human Genome Agilent array technology was applied and a whole transcriptome 
analysis was performed. We have identified gene expression perturbations, associated pathways and 
molecular functions induced by RuT7 complex treatment of HeLa cells. Additionally, we have assessed 
in silico the potential drug sensitivity and toxicity effects of RuT7 complex in comparison to cisplatin 
treatment. Therefore, the main objectives of this study were to identify significantly enriched biological 
functions and canonical pathways as a result of drug treatment at 12 and 24 h time points, to identify 
gene clusters whose expression changes over the time (time-course) and to identify differences in 
predicted toxicity profiles between cells treated with RuT7 complex and cisplatin. 
 
2. Materials and Methods 
2.1 Cell lines and culture conditions 
The human cervical carcinoma (HeLa) cells were maintained as a monolayer culture in the 
Roswell Park Memorial Institute (RPMI) 1640 nutrient medium (Sigma Chemicals Co, USA). RPMI 
1640 nutrient medium was prepared in sterile deionised water, supplemented with penicillin (192 
IU/mL), streptomycin (200 µg/mL), 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) (25 
mM), L-glutamine (3 mM), and 10% of heat-inactivated fetal calf serum (FCS) (pH 7.2). The HeLa 
cells were grown at 37 °C in 5% CO2 in a humidified air atmosphere. 
 
2.2 Cell cycle analysis 
Flow-cytometric analysis of the cell cycle phase distribution of HeLa cells, treated with 
investigated ruthenium complex and CDDP as reference compound was performed after staining fixed 
HeLa cells with propidium iodide (PI) [26]. 
HeLa cells were seeded at a density of 2 x 10
5
 cells/well, in 6-well plates (NUNC), and grown in 
complete nutrition medium. After 24 h, the cells were continually exposed to tested compound and 

















[12]). After 24 and 48 h of continual treatment, the cells were collected by trypsinization, 
washed twice with ice-cold PBS, and fixed for 30 min in 70% EtOH. After fixation, the cells were 
washed again with PBS, incubated with RNaseA (1 mg/mL) for 30 min at 37 C and stained with PI 
(400 µg/mL) 15 min before flow-cytometric analysis. Cell cycle phase distribution was analyzed using 
a fluorescence activated sorting cells (FASC) Calibur Becton Dickinson flow cytometer and the Cell 
Quest computer software. 
 
2.3 Apoptotic assay 
Induction of apoptosis by RuT7 complex and CDDP in HeLa cells was evaluated by Annexin V–
FITC apoptosis detection kit (BD Biosciences Cat. No. 65874x, Pharmingen San Diego, CA, USA). 
Briefly, 1 x 10
6
 HeLa cells/mL were treated with 0.5 x IC50 and IC50 concentrations of RuT7 complex 
and CDDP for 24 h. After treatment the cells were washed twice with cold PBS and then resuspended in 
200 μL binding buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). 100 μL of the 
solution (1 x 10
5
 cells) was transferred to a 5 mL culture tube and 2.5 μL of Annexin V–FITC and 2.5 
μL of PI were added. The cells were gently vortexed and incubated for 15 min at 25 C in the dark. 
Next, 400 μL of binding buffer was added to each tube and then analyzed using a FACS Calibur Becton 
Dickinson flow cytometer and the Cell Quest Pro computer software. 
 
2.4 Morphological evaluation of HeLa cell death 
To examine the mode of HeLa cell death induced by the investigated compound, morphological 
analysis by microscopic examination of acridine orange/ethidium bromide-stained target cells was 
performed. HeLa cells were seeded overnight on coverslips in 6-well plates (1.5 x 10
5
 cells per well) in 
2 mL of complete nutrient medium. After 24 h, the cells were treated with investigated ruthenium 
compound for 3, 5 and 24 h at concentrations corresponding to 0.5 x IC50 values that were obtained 
after treatments that lasted 48 h. After this period, the target cells were stained with 10 µL of a mixture 
of the DNA dyes acridine orange and ethidium bromide (3 µg/mL AO and 10 µg/mL EB in PBS), and 















using AxioCam MRm (filters Alexa Fluor 489 and Alexa Fluor 546) using the Fluar 10x/0.30 M27 and 
LD Plan-NeoFluar 40x/0.60 Corr Ph2 M27 objectives. Images were obtained with multidimensional 
acquisition using digital imaging software (AxioVision Version 4.7; Carl Zeiss Imaging Solutions). 
 
2.5 Inductively coupled plasma mass spectrometry (ICP-MS) 
Ru accumulation was analyzed in HeLa cells with inductively coupled plasma mass spectrometry 
(ICP-MS) using Thermo Scientific iCAP Qc ICP-MS (Thermo Scientific, Bremen, Germany) [27]. 
HeLa cells were seeded at 1 x 10
6
, 0.7 x 10
6
 and 0.5 x 10
6 
densities in a 25 cm
2
 falcon dish (Thermo 
Scientific Nunc™) for 6, 24 and 48 h treatment, respectively. After 24 h stabilization period, the cells 
were treated with the RuT7 complex at concentration equal to 1 x IC50. Following 6, 24 and 48 h, the 
cells were harvested by scraping, washed by ice cold PBS and the cell pellet was collected by 
centrifugation at 2000 rpm, 10 min. 
 
2.6 HeLa treatment and RNA extraction protocol 
HeLa cells were seeded in triplicate, at 1 x 10
6 
and 0.7 x 10
6
 densities in a 25 cm
2
 falcon dish 
(Thermo Scientific Nunc™) for 12 and 24 h treatment, respectively. At 24 h after seeding, the cells 
were treated with 0.5 x IC50 concentrations of RuT7 complex, CDDP, or left untreated as control. 
Following 12 and 24 h, the cells were harvested and total RNA was extracted using the Trizol reagent 
(Invitrogen), and purified using the RNeasy Mini Kit (QIAGEN). RNA quantity and quality was 
estimated using the BioSpec Nano spectrophotometer (Shimadzu Scientific Instruments) and 1% 
agarose gel electrophoresis. 
  
2.7 Microarray hybridization procedure 
Briefly, 100 ng of total RNA per sample was labeled with Cy3 fluorescent dye using the Low 
Input Quick Amp Labeling Kit (Agilent Technologies, Santa Clara, CA, USA) and subsequently 
hybridized over 17 h at 65ºC onto an Agilent SurePrint G3 Hmn GE 8x60 K microarray, covering 















(control, RuT7 and CDDP) at each time point (12 h and 24 h), for a total of 18 samples. Detailed 
description of procedures for sample labeling and microarray hybridization is in Supplementary 
Methods. 
 
2.8 Microarray data pre-processing and data analysis 
Processed slides were scanned with the Agilent SureScan Microarray Scanner (Agilent 
Technologies) and images were processed using the Agilent Feature Extraction v.11 software (Agilent 
Technologies). Quality Control report was used to evaluate the reliability and reproducibility of each 
microarray, and 2 samples were discarded from further analysis. Microarray data pre-processing and 
differential expression analysis was performed using the GeneSpring v.13.1 software (Agilent 
Technologies). In brief, flagged probes and control probes were filtered out, raw intensity values were 
averaged over the replicate probes, and background corrected data was normalized by scaling to 75
th
 
percentile and log 2 transformed. Additionally, sample quality control was performed by principal 
component analysis and 3 outlier samples were excluded from further downstream analysis. Microarray 
dataset is publicly available at the GEO database (http://www.ncbi.nlm.nih.gov/geo/info/linking.html) 
under GSE72905 accession number. 
A moderated t-test was applied to identify differentially expressed genes between treatment 
conditions, and the estimated significance levels (unadjusted p-values) were corrected for multiple 
hypotheses testing using Benjamini and Hochberg false discovery rate (FDR) adjustment [28]. Genes 
with less than 0.05 false discovery rate (q-value) and greater than 2-fold differences in expression 
between the groups were considered to be significantly differentially expressed.  
Supervised clustering analysis, applying average linkage method and Pearson uncentered 
correlation coefficient, was performed using the Cluster 3.0 software [29] and visualized using the 
JavaTreeView (http://jtreeview.sourceforge.net).  
Time-course analysis of gene expression changes between different conditions was performed 
using the MaSigPro algorithm implemented within the Babelomics 4.0 bioinformatics suite 















Trajectory plots were used to visualize the results as time-dependent changes of gene expression 
between control and treated cells. Details of the analysis are described in the Supplementary Methods. 
 
2.9 Gene set enrichment analysis and functional annotation 
Ingenuity Pathway Analysis software (http://www.ingenuity.com) was used to identify pathways 
or biological functions that are with statistically significant over-representation in a given gene list, by 
applying the Fisher exact test [32]. All P values were corrected for multiple testing by Benjamini and 
Hochberg false discovery rate (FDR) adjustment; significance threshold was set to 0.05 FDR. IPA Core 
Analysis was performed to identify canonical signaling pathways, biological processes and gene 
networks significantly associated with drug-induced changes in gene expression for each treatment and 
time point. IPA Core Comparison analysis was performed to identify differences in enriched pathways 
between treatment-time points. Finally, IPA Tox Analysis was used to identify molecule-to-phenotype 
associations for known toxicities significantly enriched in the differentially expressed gene list for each 
of the compounds at 12 and 24 h time points. All IPA analyses are described in detail in Supplementary 
Methods. 
We have applied GOEAST - Gene Ontology Enrichment Analysis Software Toolkit [33] to 
identify significantly enriched gene ontology terms (GO) among the lists of genes belonging to specific 
Clusters, by inspecting both top significant GO terms and significant higher level GO functions. GO 
Term enrichment was calculated using hypergeometric probability distribution and the p-values were 
adjusted for multiple testing by controlling the false discovery rate (FDR) applying the Benjamini–
Hochberg–Yekutieli procedure [34]. The significance threshold was set to 0.01 FDR. 
3. Results 
3.1 Cell cycle analysis 
The effect of the investigated ruthenium(II)-arene complex (RuT7) and cisplatin (CDDP) on cell 
cycle progression of HeLa cells was examined by flow cytometry after continual treatment for 24 and 
48 h, using staining with PI. HeLa cells were exposed to 0.5 x IC50 and IC50 concentrations of RuT7 
















Figure 2. Effects of RuT7 and CDDP on cell cycle distribution. Untreated (control) HeLa cells or HeLa 
cells treated for 24 h (A) and 48 h (B) with 0.5 x IC50 and IC50 concentrations of RuT7 (22.7 and 45.4 
µM) and CDDP (2.6 and 5.2 µM). The results are expressed as mean ± standard deviations of three 
independent experiments. 
 
Following 24 h treatment with RuT7, as shown in the Figure 2A, we observed a dose-dependent 
increase in sub-G1 population of cells with fragmented DNA (up to 20% with IC50) compared to control 
(3%), and CDDP-treated cells (up to 8%), with a corresponding decrease in the fraction of cells in the 
G1 phase compared to control cells with both concentrations applied. Interestingly, RuT7 and CDDP 
treatment with 0.5 x IC50 concentrations (22.7 and 2.6 µM, respectively) resulted in accumulation of 















concentrations. Moreover, in contrast to a more than 2-fold reduction of percent of cells in G2 phase 
caused by CDDP treatment, compared to control in both concentrations applied, significantly larger 
number of cells manages to enter the G2 phase after RuT7 treatment. 
After 48 h treatment with RuT7, the cell cycle profile (Figure 2B) shows a more pronounced 
decrease of percent of cells in G1 phase (down to 27% compared to control population). This was 
accompanied by an enhanced accumulation of cells in S phase, which was positively correlated to the 
RuT7 concentration increase (35% and 44%, respectively). A similar trend in accumulation of cells in 
the S phase is present after CDDP treatment (up to 51%). It should be pointed out that after RuT7 
treatment, a significantly higher number of cells proceeds to G2 phase, compared to CDDP treatment, 
which may indicate differences in the mechanism of action of RuT7 complex and CDDP, or differences 
in the cell defense response to RuT7 complex and CDDP treatment. 
 
3.2 Apoptotic assay 
The potential of RuT7 and CDDP to induce apoptotic cell death was determined by staining 

















Figure 3. Apoptosis induction potential of RuT7 and CDDP. Cells were treated for 24 h with 0.5 
x IC50 and IC50 concentrations of RuT7 (22.7 and 45.4 µM) and CDDP (2.6 and 5.2 µM); FITC(-)/PI(-) 
are live cells, FITC(+)/PI(-) are early apoptotic cells, FITC(+)/PI(+) are late apoptotic or necrotic cells 
and FITC(-)/PI(+) are dead cells. The results are expressed as mean ± standard deviations of three 
independent experiments 
 
Results after 24 h of exposure of HeLa cells to RuT7 reveal an increased number of cells in 
FITC(+)/PI(+) and FITC(-)/PI(+) subpopulations (Figure 3). At the same time, the number of living 
cells with intact membranes that exclude both markers (FITC(-)/PI(-)) decreases, even more drastically 
with the increase of concentration of RuT7. Treatment with CDDP under the same experimental 
conditions did not induce prominent effects on HeLa cells for this incubation period. 
 
3.3 Morphological evaluation of HeLa cell death 
In order to confirm the apoptotic potential of the investigated complex, a morphological analysis 
by fluorescence microscopy of acridine orange/ethidium bromide-stained HeLa cells exposed for 3 - 24 
















Figure 4. Photomicrographs of acridine orange/ethidium bromide-stained control (C) HeLa cells and 
HeLa cells exposed for 3 and 5 h to complex RuT7 (left), and photomicrographs of acridine 
orange/ethidium bromide-stained control (C) HeLa cells and HeLa cells exposed for 24 h to complex 
RuT7 (right). Red arrows point to cytoplasmic shrinkage and nuclear condensation; blue arrows denote 
membrane blebbing structures. Scale bars in the upper images correspond to magnification of 
photomicrographs below. Applied concentrations of RuT7 corresponded to 22.7 µM (0.5 x IC50) values 
determined for 48 h incubation period 
 
Control HeLa cells presented on photomicrographs in Figure 4 are light green in color, elongated 
and spindle-shaped. Already after 3 h of treatment with RuT7, a reduction in cell number is obvious; 
cells lose their normal morphology and became rounded. Early apoptotic markers such as cytoplasmic 
shrinkage and nuclear condensation are present after RuT7 treatment. The most prominent 
morphological feature in Figure 4 is membrane blebbing 5 h after treatment, which is unambiguous 
hallmark of apoptosis. Furthermore, after 24 h of treatment with ruthenium(II) complex, remaining 
















3.4 Intracellular accumulation of investigated RuT7 complex 
The total intracellular accumulation of ruthenium after 6, 24 and 48 h of treatment with RuT7 at 
1x the IC50 concentration was analyzed with ICP-MS [27]. 
Figure 5 shows that after 6 h of treatment with RuT7, 8.90 ng Ru/10
6
 cells was found 
intracellular. The level of ruthenium remained stable with only a minor drop to 7.09 ng Ru/10
6
 cells 
after 24 h of continual treatment. At 48 h of exposure, the intracellular ruthenium concentration was 
significantly increased to 11.92 ng Ru/10
6
 cells. These results indicate a long-term retention of the 
ruthenium metal inside the tumor cells.  
 
Figure 5. Total intracellular accumulation of ruthenium in HeLa cells after 6, 24 and 48 h, measured by 
ICP-MS. All experiments were performed in triplicate and presented with corresponding standard 
deviations (SD). 
3.5 Differences in gene expression response to cisplatin and RuT7 treatment in HeLa cells 




















6A). The changes in gene expression induced by the RuT7 complex were compared to HeLa cells 
treated with cisplatin (CDDP) at both time points. To identify significantly differentially expressed 
genes (DEG) induced by treatment with RuT7 complex or CDDP relative to control (untreated) cells at 
both time points, we performed a moderated limma t-test (Supplementary Table 1-4). Treatment with 
RuT7 resulted in more subtle gene expression perturbation compared to the changes induced by CDDP 
treatment at both time points (Figure 6B). Treatment with RuT7 induced significant expression changes 
at 12 h compared to control cells in 2415 unique annotated genes, with 1184 upregulated and 1243 
downregulated genes. The effect was potentiated at 24 h, with a total of 5988 DEG, of which 5475 were 
upregulated and only 545 downregulated. Top 20 significantly differentially expressed genes in 
response to RuT7 are shown in Table 1. 










12 h treatment 
LAT2 
Linker for activation of T cells 
family, member 2 
2.4 x 10
-7
 3.2 x 10
-3
 26.6 ↑ 
OTOA Otoancorin 3.0 x 10
-7
 3.2 x 10
-3
 33.6 ↑ 
FBXW10 




 3.2 x 10
-3
 36.9 ↑ 
BRD8 Bromodomain containing 8 1.8 x 10
-7
 3.2 x 10
-3
 43.1 ↑ 
FOXD4 Forkhead box D4 5.5 x 10
-7
 3.9 x 10
-3
 19.0 ↑ 
MYH3 




 3.9 x 10
-3
 20.0 ↑ 
SV2B Synaptic vesicle glycoprotein 2B 2.4 x 10
-6
 4.3 x 10
-3
 -10.0 ↓ 
EDN2 Endothelin 2 2.5 x 10
-6
 4.3 x 10
-3
 -10.0 ↓ 
COL9A3 Collagen, type IX, alpha 3 2.5 x 10
-6
 4.3 x 10
-3




















 4.3 x 10
-3
 -6.7 ↓ 
LOC91450 Uncharacterized LOC91450 2.5 x 10
-6
 4.3 x 10
-3
 6.8 ↑ 
PLAC8L1 PLAC8-like 1 2.1 x 10
-6
 4.3 x 10
-3
 7.0 ↑ 
VWCE 




 4.3 x 10
-3
 7.2 ↑ 
RNF151 Ring finger protein 151 2.9 x 10
-6
 4.3 x 10
-3
 8.0 ↑ 
ELMO3 Engulfment and cell motility 3 3.0 x 10
-6
 4.3 x 10
-3
 8.6 ↑ 
AOC3 




 4.3 x 10
-3
 8.8 ↑ 
CARD9 
Caspase recruitment domain 
family, member 9 
1.4 x 10
-6
 4.3 x 10
-3
 9.1 ↑ 
C17orf51 




 4.3 x 10
-3
 9.3 ↑ 
IFFO1 




 4.3 x 10
-3
 11.6 ↑ 
24 h treatment 
MAP2 Microtubule-associated protein 2 5.7 x 10
-5
 2.3 x 10
-2
 -15.4 ↓ 
CLIC3 Chloride intracellular channel 3 5.3 x 10
-6
 2.3 x 10
-2
 -12.5 ↓ 
PRUNE2 Prune homolog 2 (Drosophila) 5.9 x 10
-4
 2.3 x 10
-2
 -10.7 ↓ 
KCNU1 




 2.3 x 10
-2
 -10.1 ↓ 
TNNC1 Troponin C type 1 (slow) 3.9 x 10
-4
 2.3 x 10
-2
 -9.8 ↓ 
SPOCK3 
Sparc/osteonectin, cwcv and 




 2.3 x 10
-2
 -8.4 ↓ 
PRSS56 Protease, serine, 56 1.5 x 10
-4
 2.3 x 10
-2
 -8.1 ↓ 
C1orf140 Uncharacterized LOC400804 3.3 x 10
-4
 2.3 x 10
-2
 -8.0 ↓ 
TP53INP1 
Tumor protein p53 inducible 
nuclear protein 1 
5.7 x 10
-5
 2.3 x 10
-2
 -7.5 ↓ 
LGSN 
Lengsin, lens protein with 
glutamine synthetase domain 
9.2 x 10
-5
 2.3 x 10
-2
















Latent transforming growth factor 
beta binding protein 1 
4.5 x 10
-4
 2.3 x 10
-2
 -7.4 ↓ 
FLJ37201 
Tigger transposable element 
derived 2 pseudogene 
1.9 x 10
-5
 2.3 x 10
-2
 -6.6 ↓ 
ITGBL1 
Integrin, beta-like 1 (with EGF-
like repeat domains) 
6.8 x 10
-6
 2.3 x 10
-2
 -6.6 ↓ 
ITGA1 Integrin, alpha 1 6.1 x 10
-4
 2.3 x 10
-2
 -6.5 ↓ 
ASZ1 
Ankyrin repeat, SAM and basic 




 2.3 x 10
-2
 -6.3 ↓ 
SEMA3D 
Sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3D 
1.7 x 10
-4
 2.3 x 10
-2
 -6.0 ↓ 
OLFML2A Olfactomedin-like 2A 1.7 x 10
-4
 2.3 x 10
-2
 -6.0 ↓ 
COL12A1 Collagen, type XII, alpha 1 3.7 x 10
-4
 2.3 x 10
-2
 -6.0 ↓ 
INSL4 Insulin-like 4 (placenta) 4.7 x 10
-5
 2.3 x 10
-2
 -5.9 ↓ 
 
 
Supervised hierarchical clustering (Figure 7) over most variable significantly differentially 
expressed genes in RuT7 treated cells at 12 and 24 h reveals time-dependent changes in RuT7 activity 

















Figure 6. A. Experimental procedure outline B. Number of differentially expressed genes (DEG) at 12 
and 24 h in HeLa cells treated with RuT7 or CDDP compared to control. C. Venn diagrams 
representing specific and commonly deregulated genes (FDR<0.05 and FC>2) in HeLa cells at 12 and 
24 h upon treatment with RuT7 (in red) and CDDP (in green) 
 
Conversely, cisplatin treatment induced a strikingly greater level of gene expression perturbations 
at both 12 and 24 h, with a total of 8103 (96 upregulated and 8025 downregulated) and 11263 
differentially expressed genes (998 upregulated and 10416 downregulated), respectively. At 12 h, 
cisplatin induced extensive gene expression perturbation with 7347 CDDP-specific DEG, in contrast to 
moderate changes in gene expression in RuT7 treated cells (1659 RuT7-specific DEG), with only 756 
genes commonly deregulated genes between RuT7 and CDDP treated cells (Figure 6C). After 24 h 
treatment, more prominent changes in gene expression were observed in RuT7 treated cells, with ~60% 
















Figure 7. Heatmap representing supervised hierarchical clustering over most variable (above mean 
standard deviation) significantly differentially expressed genes between RuT7 and control treated HeLa 
cells. A) at 12 h; B) at 24 h. Genes expressed above median are pseudo-colored in red, bellow median in 
green. C) Venn diagram showing specific and common differentially expressed genes in HeLa cells 
treated with RuT7 at 12 and 24 h. 
 
3.6 Kinetics and functional analysis of RuT7-induced gene expression changes  
Through differential expression analysis we observed time-dependent changes in expression in 
RuT7 treated HeLa cells. Gene expression profiles of RuT7 treated HeLa cells are markedly different 
after 12 h (Figure 7A) and 24 h (Figure 7B), with only 759 commonly deregulated genes at both time 
points (Figure 7C). 
To identify drug-specific genes and to further explore the kinetics of gene expression changes in 
cells treated with RuT7 complex we applied a multivariate regression-based algorithm MaSigPro. The 















show significant changes between 12 and 24 h time points, that differ between RuT7 treated cells and 
the control population (Figure 8). A full list of genes belonging to each cluster and associated 
coefficients and p-values are represented in Supplementary Table 5. To determine the biological 
relevance of gene expression changes associated with each cluster independently, we performed an 
over-representation analysis using Gene Ontology Enrichment Analysis Software Toolkit (GOEAST) 
that allows determination of significantly enriched GO terms within a gene set, compared with the 
frequency among all genes on the array. This analysis aimed at an understanding of the effect of the 
modulation of gene expression on particular functional categories (biological process, molecular 
function, and cellular component). Full list of GO categories identified as significantly enriched (p < 
0.01) among the genes is shown in Supplementary Tables 6-14. 
Drug-induced changes in gene expression were observed for Cluster 2, 3 and 5 genes. Cluster 2 
included 2938 highly expressed genes that were consistently downregulated, while 540 genes belonging 
to Cluster 3 were consistently upregulated in RuT7 treated cells with similar degree of time-dependent 
changes in control and RuT7 treated cells. Genes belonging to Cluster 5 (1470) were induced in RuT7 
treated cells while being expressed at a constant rate over time in control cells. Functional 
characterization of genes belonging to drug-specific genes clusters with constant response (Cluster 2, 3 
and 5) indicated that Cluster 2 was significantly enriched for GO molecular functions related 
specifically to hydrolase and oxidoreductase catalytic activity and ion binding, while significantly 
enriched biological functions included organic substance metabolic process and ATPase activity 
coupled to transmembrane movement of ions. Both Cluster 3 and 5 genes were significantly enriched 
for molecular functions related to nucleic acid binding, heterocyclic compound bounding and transition 
metal ion binding, where top biological functions were related to general metabolic processes. 
Early response genes following RuT7 treatment were identified in Cluster 6 (930) showing strong 
induction at 12 h followed by a drop in expression at 24 h to the level of control cells, and in Cluster 8 
with 649 genes that were repressed at 12 h in RuT7 treated cells followed by an increase in expression 
at 24 h. Significantly enriched molecular functions for upregulated early response genes belonging to 















binding in addition to histone methyltransferase activity and biological processes histone acetylation, 
negative regulation of transcription and intrinsic apoptotic signaling pathway in response to DNA 
damage by p53 class mediator. Downregulated early response genes (Cluster 8) had only a few 
significant molecular functions, among which are WW domain binding and transferase activity, 
transferring acyl groups molecular function and regulation of spindle organization and M phase of 
mitotic cell cycle as biological processes localized to cellular compartments Ndc80 complex, nuclear 
chromosome and centrosome. 
RuT7 treatment-specific genes with delayed response were identified in Cluster 1 and Cluster 7. 
Cluster 1 contained 2722 low-expressed genes which demonstrated significant change in induction 
along time, while 410 highly expressed genes in Cluster 7 were significantly repressed at 24 h. G-
protein coupled receptor activity, intracellular cAMP activated cation channel activity, signal transducer 
activity and cell communication and response to stimulus were significantly over-represented among 
upregulated low expressed late response genes belonging to Cluster 1 with cellular compartment 
localization to plasma membrane, and intermediate filaments. Top GO terms for downregulated late 
response genes belonging to Cluster 7 included enzyme regulator activity, protein serine/threonine 
kinase inhibitor activity and mismatch base pair DNA N- glycosilase activity, nuclear replication fork, 
microtubule organizing centre, regulation of cyclin-dependant serine/threonine kinase activity and 

















Figure 8. Group plots show the direction of expression changes for each gene cluster over time (12 h 
and 24 h) measurements and the differences between the RuT7 (green) and control-treated cells (red). 
Genes are clustered by similar patterns and an average gene expression level is represented for each 
cluster, with associated 95% CI (upper and lower dots). The slope coefficient represents the values of 
the estimated regression coefficients, positive for induced gene clusters, negative for repressed gene 
clusters. 
  
RuT7 treatment showed strong effect modification on expression of time-dependent genes 















RuT7 treatment at 12 h followed by a significant drop in expression at 24 h, in contrast to control 
treated cells exhibiting inverse direction of changes of expression, while genes belonging to Cluster 9 
had opposite direction of expression changes. 
  
3.7 Differences in toxicity profiles of RuT7 and CDDP treated HeLa cells  
Cell cycle analysis highlighted potential differences in cellular response to RuT7 and CDDP. To 
gain a better understanding of the underlying biological processes in RuT7 or CDDP treated cells at 12 
and 24 h time points, we interrogated the list of the differentially expressed genes using Ingenuity 
Pathway Analysis® software (IPA, Ingenuity Systems, Redwood City, CA). All canonical pathways, 
biological functions and networks significantly enriched in RuT7 and CDDP treated cells at 12 and 24 h 
time points are represented in Supplementary Tables 15-18. 
Both at 12 and 24 h top enriched biological functions in RuT7 treated cells were related to cell 
death and survival, cellular compromise, nucleic acid metabolism, small molecule biochemistry, cell-to-
cell signaling and interaction, molecular transport, cellular development, cellular growth and 
proliferation, drug metabolism and cell cycle. Additionally, at 12 h HeLa cells treated with RuT7 show 
significant enrichment of genes belonging to RNA damage and repair, free radical scavenging, DNA 
replication, recombination, and repair, protein synthesis, protein trafficking biological functions. 
Canonical pathways enriched both at 12 and 24 h in RuT7 treated cells included estrogen biosynthesis, 
agranulocyte adhesion and diapedesis, and metabolic degradation pathways.  
We examined genes and pathways differentially modulated in response to RuT7 and CDDP. 
While many pathways and biological functions were commonly enriched (Supplementary Figures 1-
2), there were specific effects of RuT7 reflected by the induction of genes belonging to estrogen 
biosynthesis and metabolite degradation canonical pathways, while CDDP treated cells had markedly 
stronger association with calcium transport and citruline metabolism canonical pathways and biological 
functions of antimicrobial response and molecular transport. To predict potential toxicities associated 
with RuT7 treatment we performed IPA Tox Comparison Analysis on differentially expressed genes at 















predicted toxicity profile (Figure 9), with CDDP-treated cells showing strong enrichment at 24 h for 
genes involved in cardiac arrhythmia, cardiac infarction and kidney failure while RuT7 had no 
significantly associated toxicity functions.  
 
Figure 9. Bar chart depicting significantly enriched (FDR<0.05) toxicity functions determined by IPA 
Tox Comparison Analysis 
 
4. Discussion 
Extensive investigation of alternative transition metal-based cancer therapies to platinum-based 
drugs have been conducted since the initial discovery of cisplatin anticancer properties [35]. 
Ruthenium-based compounds have emerged as promising drug candidates because of their properties 
such as the rate of ligand exchange, the range of accessible oxidation states and the ability of ruthenium 
to mimic iron in binding to certain biological molecules [36]. Lately, ruthenium(II)-arene complexes are 
in the limelight of ruthenium-based anticancer compound research, due to their stability, water 
solubility and structure manipulation susceptibility, providing space for design optimization, which 
works in terms of increasing their biological activity and minimizing side-effects [37]. Our previous 
study has shown the antiproliferative potential of ruthenium(II)-arene complex with isoquinoline-3-
carboxylic acid as ligand (RuT7) on cancer cells [12]. Having in mind wide range of potential 

















-p-cymene)(isoquinoline-3-carboxylic acid)Cl] (RuT7) in comparison with widely used 
clinical chemotherapeutic agent cisplatin, through analysis of changes in cell cycle profile and apoptotic 
potential. Besides investigation of in vitro cellular response, for the first time, a whole-transcriptome 
microarray gene expression analysis in HeLa cells treated with ruthenium(II)-arene complex has been 
performed in order to elucidate gene expression alterations in cancer cells after ruthenium-based drug 
exposure. Predicted toxicity profiles for RuT7 and CDDP have also been assessed and compared. 
Inhibition of DNA replication is a well-known feature of the cisplatin mechanism of action, which 
is reflected in our data through accumulation of cells in S phase after CDDP treatment [38]. Likewise, 
arrest in the S phase of cell cycle indicates possible binding to and/or damage of DNA by RuT7 
complex, leading to consequent replication inhibition of cancer cells. Already after 24 h treatment with 
lower concentrations of RuT7 applied (0.5 x IC50), prominent S phase accumulation is obtained. These 
results are in the compliance with our previous study of the biological activity of similar ruthenium 
complexes [Ru(η
6
-p-cymene)(L)Cl2], where the complex with picolinic acid as the ligand L exerted it´s 
cytotoxic effect through cell cycle arrest in the S phase and significant intracellular distribution in DNA 
rather than protein fraction of treated cells, indicating DNA as target of its action [39]. After 24 h of 
continual treatment of HeLa cells with RuT7, an observed increase of Sub-G1 phase denotes apoptotic 
and/or necrotic population of cells. However, doubling the concentration of RuT7 increases sub-G1 
population of HeLa cells drastically, that may be interpreted as contribution of general toxicity of RuT7 
complex. These results point out the importance of determining the proper concentration of drug. 
From these results we can conclude that growth inhibition of HeLa cells by RuT7 complex like 
cisplatin involves a profound cell cycle arrest in S phase, indicating its potential of interaction with 
DNA. These results are in concordance with the results of our previous DNA binding study by UV 
spectroscopic titration which demonstrated DNA binding potential of RuT7 complex [13]. 
Phosphatidylserine (PS) externalization is one of early hallmarks that denote apoptosis, the 
process of programmed cell death. Annexin V, a Ca
2+
-dependent phospholipid-binding protein, has high 
affinity for PS, and in conjunction with the proper fluorochrome, fluorescein isothiocyanate (FITC) can 















lasted 24 h, HeLa cells exposing PS on its surface were monitored. Compared to control, an increase in 
early apoptotic cell fraction (FITC(+)/PI(-)) was not obtained, neither for RuT7 complex nor CDDP. 
However, there is a prominent increase in late apoptotic and/or already dead cells (FITC(+)/PI(+)), as 
well as increase in dead cells number (FITC(-)/PI(+)) after RuT7 treatment (Figure 3). Absence of early 
apoptotic fraction of cells can be explained by possible fast and immediate action of RuT7 complex, 
where after 24 h of incubation period majority of early apoptotic cells have already proceeded to late 
apoptotic stage. These results are in correlation with the appearance of sub-G1 fraction of cells in cell 
cycle phase distribution analyses (Figure 2). 
Typical morphological features of the apoptotic cells are highly condensed nuclei, cell shrinkage 
and formation of apoptotic bodies. In the early apoptosis, only acridine orange enters the cell with 
ethidium bromide excluded and the nucleus stains green. In the late apoptosis along with the loss of 
membrane integrity, both dyes enter the cell and the nucleus becomes orange-red [42]. After only 3 h of 
treatment with RuT7, changes in morphological features of HeLa cells are obvious, when compared to 
control HeLa cells. Decreased density/cell number, round shape and beginning of nuclear condensation 
are the most prominent features after 3 h of treatment. Already after 5 h of incubation with RuT7, 
highly condensed nuclei and membrane blebbing are predominant hallmarks. These findings, together 
with photomicrographs obtained after 24 h of continual treatment are in concordance with the results of 
Annexin V-FITC assay, and represent confirmation of hypothesized fast, nearly immediate RuT7 
action. The continuous presence of cells with apoptotic morphology can be explained with persistent 
intracellular accumulation of RuT7 (Figure 5). Morphological analysis by fluorescence microscopy of 
acridine orange/ethidium bromide-stained HeLa cells exposed to RuT7 has undoubtedly proven 
apoptosis-inducing potential of investigated complex, which is one of the main prerogatives for 
successful chemotherapeutic agent. 
ICP-MS analysis of total intracellular accumulation of ruthenium has shown time-dependent 
increase of intracellular ruthenium content. High intracellular ruthenium concentration already after 6 h 
of incubation (8.83 ± 0.09 ng Ru/10
6
 cells) is in agreement with previous conclusions about very fast 















transmembrane transport of this compound. Due to the presence of arene ligand [43-45], as well as 
isoquinoline-3-carboxylic acid (derivative of picolinic acid with fused phenyl group), which 
significantly contribute to lipophilicity of the complex [46-53], passive transport through hydrophobic 
lipid bilayer is plausible. Through the course of time, ruthenium holds and even increases its 
concentration inside cells (24 and 48 h incubation, respectively, Figure 5). This implicates binding of 
RuT7 to intracellular structures and its continuous accumulation in intracellular environment [54]. 
  It is clear from the results above that, on cellular level, RuT7 exhibited cytotoxic effect 
comparable to CDDP. However, this effect is reflected on molecular level as more subtle perturbation 
of HeLa cell transcriptome. Besides overall lower level of gene expression perturbations induced by 
RuT7 complex, different mechanism of action is visible from schematic representation of specific and 
commonly deregulated genes in HeLa cells at 12 h and 24 h upon treatment with RuT7 and CDDP 
(Venn diagrams, Figure 6C). After 12 h of treatment, 1659 RuT7-specific DEG has been found, which 
were not deregulated in CDDP-treated population. These results provide evidence that, during this 
‘early response’ to treatment (12 h), different molecular mechanisms are active after RuT7 and CDDP 
treatment. 
Analysis of gene clusters with similar expression patterns gave us valuable informations 
concerning mechanism of RuT7 action. RuT7 treatment induced consistent upregulation of genes 
implicated in nucleic acid binding, heterocyclic compound bounding and transition metal ion binding 
(Clusters 3, 5 and 6). Besides the strong implication of DNA binding of RuT7 inside the living cell, 
these data also provide information about interactions of transition metal by itself, as well as interaction 
of heterocyclic ligand with cells’ genetic material. This could possibly indicate binding of the whole 
organometallic complex to cells’ DNA, as previously demonstrated in vitro [12], which confirms its 
stability in physiological conditions. Moreover, upregulation of early response genes of Cluster 6 that 
are included in GO biological functions histone acetylation, negative regulation of transcription and 
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator, clearly 
indicate activation of the DNA damage response (DDR), which represents a coordinated series of 















accessibility of the repair machinery to lesions embedded in chromatin [55]. Enrichment of intrinsic 
apoptotic signaling pathway in response to DNA damage by p53 class mediator provides a strong 
confirmation of results obtained by flow cytometry and acridine orange/ethidium bromide staining. As 
hypothesized, apoptotic signaling pathway takes place shortly after RuT7 treatment (Cluster 6 genes 
showing strong induction at 12 h), consequently yielding large number of late apoptotic and/or dead 
cells at 24 h time point (Figure 3). 
Downregulated early response genes included in Cluster 8, describing biological functions of 
Regulation of spindle organization and M phase of mitotic cell cycle, indicate possible mitosis 
inhibition. There are numerous literature data about ruthenium(III) complexes exhibiting similar 
mechanism of action [56-59]. Likewise, significantly repressed late response genes (at 24 h) belonging 
to Cluster 7, included in Regulation of transcription involved in G1/S phase of mitotic cell cycle and 
similar biological functions, denotes treatment-induced G1/S phase arrest. This is in a good agreement 
with our results of cell cycle analysis, where 0.5 x IC50 concentration-induced S-phase arrest after 24 h 
of treatment is prominent feature (Figure 2). 
In further analysis we tried to shed light on involvement of DEGs in specific biological functions 
and canonical pathways, and to further elucidate possible mechanisms of action of RuT7 complex. After 
12 h of RuT7 treatment, Free radical scavenging enrichment could point out on oxidative stress of HeLa 
cells, which can result from presence of reactive oxygen species. This enriched biological function 
could be connected to DNA Replication, Recombination and Repair and RNA Damage and Repair 
enriched functions, which indicate damage in DNA/RNA molecules, possibly caused by the generation 
of free radicals inside the cell. This is consistent with the literature data about ruthenium based 
complexes mechanism of action [18]. Besides DNA/RNA damage due to direct binding of RuT7 
complex to these molecules already discussed before, these findings could point out to alternative 
mechanism of RuT7 action. Protein synthesis and Protein trafficking are biological functions also 
exclusively enriched after 12 h of incubation of HeLa cells with the investigated compound. These 
functions could be connected to aforementioned DNA damage, because cell needs complex protein 















to apoptosis [38, 60-63]. This is also in agreement with top GO enriched biological functions in Clusters 
7 and 8, describing G1/S and G2/M arrest, respectively.  
Cellular growth and Proliferation, Cell cycle and Cell death are biological functions enriched at 12 
and 24 h that could be as well considered as confirmation of aforementioned results. Together, these 
functions describe genes associated with the growth and proliferation of cells, as well as stages of the 
cell cycle including cell division. Overall, these results, together with flow cytometry experiments, 
strongly indicate role of RuT7 in the cell cycle progression inhibition. Other commonly enriched 
biological functions for both incubation times (12 h and 24 h) worth mentioning are Cell-To-Cell 
signaling and Interaction together with Cellular compromise. These clearly indicate that after 12 h of 
treatment (and 24 h also) effects of RuT7 complex include disruption and damage of cells that are 
preceded by compromising intercellular junctions and/or cell-surface contacts. Our results of 
morphological analysis of HeLa cells treated with RuT7 complex and stained with AO/EtBr have 
shown that already after 3 h of treatment, cells begin to lose their normal morphology, contacts with 
other cells and become detached from the surface (Figure 5). This compromising of cells’ function 
through the direct damage of plasma membrane could be considered as a repercussion of redox activity 
of RuT7. It seems that, besides inducing oxidative stress inside the cell, ruthenium(II)-arene complex 
works directly on plasma membrane through still obscure mechanisms of action. 
Although functional gene profiling analysis revealed 12 h treatment-specific biological functions, 
after 24 h of incubation of HeLa with RuT7 complex there were no biological functions that were 
specific for this incubation period. On the contrary, number of enriched functions decreases after 24 h, 
but number of genes involved in the remaining (commonly enriched) functions increases. This, once 
again, puts emphasis on action dynamics of RuT7 complex. 
One of the major aspects of introducing new chemotherapeutics in clinical practice is certainly the 
assessment of its potential systemic toxicity. IPA Tox Comparison Analysis on differentially expressed 
genes at 12 and 24 h revealed significant differences in the predicted toxicity profile between RuT7 and 
CDDP (Figure 9). For genes involved in cardiac arrhythmia, cardiac infarction and kidney failure, 















while same toxicity functions are far below threshold for RuT7-treated cells. These results that elucidate 
molecular basis of CDDP toxicity are in concordance with the existing data on patients
 
[64-67]. These 
findings clearly demonstrate that ruthenium(II)-arene complex does not exhibit the same toxicity pattern 
as CDDP. 
According to analyzed microarray data, conclusion that RuT7 complex leads HeLa cells through 
the intrinsic (mitochondrial) apoptotic pathway can be made. It seems that DNA damage is made by the 
action of reactive oxygen species and through the direct DNA binding of organometallic complex. This 
first triggers various biological processes connected to M phase of mitotic cell cycle (downregulated 
early response genes within Cluster 8), followed by chromatin remodeling and DNA repair events 
(upregulated early response genes belonging to Cluster 6), leading eventually to blockage of DNA 
synthesis (downregulated late response genes belonging to Cluster 7). Literature data about mechanism 
of action of various ruthenium-based complexes supporting our experimental results are numerous [57, 
68-73]. Having in mind different mechanism of action of ruthenium(II)-arene complexes compared to 
CDDP, as well as differences in the predicted toxicity profiles, further efforts should be oriented 




AO acridine orange 
CDDP cis-diamminedichloroplatinum(II) 
CT calf thymus 
DEG differentially expressed gene 
















EB ethidium bromide 
FCS fetal calf serum 
GOEAST Gene Ontology Enrichment Analysis Software Toolkit 
HeLa Henrietta Lacks 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
ICP-MS Inductively coupled plasma mass spectrometry 
IPA Ingenuity Pathway Analysis 
lncRNA Long non-coding RNA 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PBS phosphate-buffered saline 
PI propidium iodide 
Roswell Park Memorial Institute RPMI 
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Figure/Table captions 
Figure 1. Structure of ruthenium(II)-arene complex RuT7, [Ru(η
6
-p-cymene)(L)Cl] 
Figure 2. Effects of RuT7 and CDDP on cell cycle distribution. Untreated (control) HeLa cells or HeLa 
cells treated for 24 h (A) and 48 h (B) with 0.5 x IC50 and IC50 concentrations of RuT7 (22.7 and 45.4 
µM) and CDDP (2.6 and 5.2 µM). The results are expressed as mean ± standard deviations of three 
independent experiments. 
Figure 3. Apoptosis induction potential of RuT7 and CDDP. Cells were treated for 24 h with 0.5 x IC50 
and IC50 concentrations of RuT7 (22.7 and 45.4 µM) and CDDP (2.6 and 5.2 µM); FITC(-)/PI(-) are live 
cells, FITC(+)/PI(-) are early apoptotic cells, FITC(+)/PI(+) are late apoptotic or necrotic cells and 
FITC(-)/PI(+) are dead cells. The results are expressed as mean ± standard deviations of three 
independent experiments 
Figure 4. Photomicrographs of acridine orange/ethidium bromide-stained control (C) HeLa cells and 
HeLa cells exposed for 3 and 5 h to complex RuT7 (left), and photomicrographs of acridine 
orange/ethidium bromide-stained control (C) HeLa cells and HeLa cells exposed for 24 h to complex 
RuT7 (right). Red arrows point to cytoplasmic shrinkage and nuclear condensation; blue arrows denote 















photomicrographs below. Applied concentrations of RuT7 corresponded to 22.7 µM (0.5 x IC50) values 
determined for 48 h incubation period 
Figure 5. Total intracellular accumulation of ruthenium in HeLa cells after 6, 24 and 48 h, measured by 
ICP-MS. All experiments were performed in triplicate and presented with corresponding standard 
deviations (SD). 
Table 1. Top-20 significantly differentially expressed genes in RuT7 treated cells compared to control 
cells 
Figure 6. A. Experimental procedure outline B. Number of differentially expressed genes (DEG) at 12 
and 24 h in HeLa cells treated with RuT7 or CDDP compared to control. C. Venn diagrams 
representing specific and commonly deregulated genes (FDR<0.05 and FC>2) in HeLa cells at 12 and 
24 h upon treatment with RuT7 (in red) and CDDP (in green) 
Figure 7. Heatmap representing supervised hierarchical clustering over most variable (above mean 
standard deviation) significantly differentially expressed genes between RuT7 and control treated HeLa 
cells. A) at 12 h; B) at 24 h. Genes expressed above median are pseudo-colored in red, bellow median in 
green. C) Venn diagram showing specific and common differentially expressed genes in HeLa cells 
treated with RuT7 at 12 and 24 h. 
Figure 8. Group plots show the direction of expression changes for each gene cluster over time (12 h 
and 24 h) measurements and the differences between the RuT7 (green) and control-treated cells (red). 
Genes are clustered by similar patterns and an average gene expression level is represented for each 
cluster, with associated 95% CI (upper and lower dots). The slope coefficient represents the values of 
the estimated regression coefficients, positive for induced gene clusters, negative for repressed gene 
clusters. 
Figure 9. Bar chart depicting significantly enriched (FDR<0.05) toxicity functions determined by IPA 

















Analysis of the cellular and molecular response of HeLa cells to RuT7 complex indicate that, after 
inducing cell cycle arrest and triggering DNA repair mechanisms, it leads HeLa cells through the 
intrinsic (mitochondrial) apoptotic pathway, via indirect DNA damage made by the action of reactive 

















 [RuCl(η6-p-cymene)(isoquinoline-3-carboxylic acid)] (RuT7) causes S phase cell cycle arrest and 
increases sub-G1 population of HeLa cells. 
 After only 3 h of treatment with RuT7 HeLa cells enter apoptosis. 
 Nearly maximum intracellular ruthenium concentration is achieved already after 6 h of incubation. 
 RuT7 leads HeLa cells through the intrinsic (mitochondrial) apoptotic pathway. 
 RuT7 does not exhibit the same toxicity pattern as cisplatin. 
